These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3628857)

  • 1. A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.
    Gennatas CS; Kalovidouris A; Paraskevas GA; Kouvaris J; Trichopoulos D; Papavasiliou C
    Radiother Oncol; 1987 Jul; 9(3):217-20. PubMed ID: 3628857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
    Rose C; Kamby C; Mouridsen HT; Andersson M; Bastholt L; Møller KA; Andersen J; Munkholm P; Dombernowsky P; Christensen IJ
    Breast Cancer Res Treat; 2000 May; 61(2):103-10. PubMed ID: 10942095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
    Alonso-Muñoz MC; Ojeda-González MB; Beltran-Fabregat M; Dorca-Ribugent J; López-López L; Borrás-Balada J; Cardenal-Alemany F; Gómez-Batiste X; Fabregat-Mayol J; Viladiu-Quemada P
    Oncology; 1988; 45(5):350-3. PubMed ID: 3045726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies with aminoglutethimide in advanced breast carcinoma.
    Harvey HA; Lipton A; Santen RJ
    Acta Clin Belg Suppl; 1986; 11():29-40. PubMed ID: 3459321
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
    Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
    S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
    Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
    Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer.
    Harris AL; Cantwell BM; Carmichael J; Dawes P; Robinson A; Farndon J; Wilson R
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1105-11. PubMed ID: 2759165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
    Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
    J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
    Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
    Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day].
    Bonneterre J; Coppens H; Mauriac L; Rouesse J; Fargeot P; Metz R; Armand JP; Mathieu A; Tubiana M; Cappelaere P
    Acta Clin Belg Suppl; 1986; 11():41-8. PubMed ID: 3521171
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
    Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC
    Lancet; 1984 Jun; 1(8391):1369-73. PubMed ID: 6145832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
    Harris AL; Cantwell BM; Sainsbury JR; Needham G; Evans RG; Dawes PJ; Wilson R; Farndon J
    Breast Cancer Res Treat; 1986; 7 Suppl():S41-4. PubMed ID: 3742063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
    Ingle JN; Green SJ; Ahmann DL; Long HJ; Edmonson JH; Rubin J; Chang MN; Creagan ET
    J Clin Oncol; 1986 Jun; 4(6):958-64. PubMed ID: 3519885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
    Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
    Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer.
    Milsted R; Habeshaw T; Kaye S; Sangster G; Macbeth F; Campbell-Ferguson J; Smith D; Calman K
    Cancer Chemother Pharmacol; 1985; 14(3):272-3. PubMed ID: 3888433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
    Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
    Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
    Grem JL; Falkson G; Love RR; Tormey DC
    Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
    Dowsett M; Harris AL; Smith IE; Jeffcoate SL
    Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen priming and response to chemotherapy in advanced prostatic cancer.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon RA; Rohner TJ; Drago J
    J Urol; 1986 Dec; 136(6):1242-6. PubMed ID: 3534315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.